FDA Expands Anktiva Label to High-Grade Papillary-Only Bladder Cancer, Broadening ImmunityBio’s Opportunity

FDA broadens Anktiva approval to papillary-only bladder cancer, giving ImmunityBio (IBRX) a larger addressable market in BCG-unresponsive NMIBC.